The principle of M-puncture — how it reads the pain circuit

01 Where it begins

Pain begins in a very thin nerve — the C-fiber and the first lesion

The body has a very thin pain nerve called the C-fiber. When it is stimulated over and over at an injured site, molecular-level changes accumulate inside it. This theory treats that first change as the starting point of pain and calls it the primary afferent molecular lesion (PML).

Two things wake the C-fiber:

• Muscle contraction — strong, repeated contraction (sensed by ergoreceptors)
• Metabolic change — local shifts such as acidity, low oxygen, lactic acid, tissue-injury products, and mast-cell/immune activity (sensed by metaboreceptors)

So PML tends to form where both receptors are dense — in muscle rather than tendon, especially thick muscles with strong contraction and a wide range of motion. Where exactly depends on the muscle’s shape (whether the origin, middle, or insertion is bulkier).

02 The spreading circuit

The first lesion spreads to cord and brain — from PML to SML

The change does not stay in the tissue. It spreads in turn to the dorsal horn of the spinal cord (SML, spinal molecular lesion) → brainstem → limbic system. In the brainstem the balance between pain-dampening descending inhibition (D.I) and pain-promoting descending facilitation (D.F) is thrown off; by the limbic system (amygdala, anterior cingulate, frontal cortex), emotional and cognitive distress is layered onto the pain.

The authors group this whole set of changes — sensitization, phenotype shifts in the nerve, disordered descending control, long-term potentiation (LTP) — under the name ‘molecular lesion.’ The textbook is explicit that this is not a standard research term, but a clinical name for the ‘molecular cascade’ set off by C-fiber activation. Its point is that single-neuron ‘sensitization’ alone does not fully account for chronic pain.

03 A third type of pain

When tissue pain and nerve pain overlap — NNPS

Pain is usually split into ‘pain from injured tissue (nociceptive)’ and ‘pain from a damaged nerve (neuropathic).’ The authors hold that in long-standing pain the two are often present at once, and propose a third type — NNPS (Nociceptive Neuropathic Pain Syndrome) that the existing two categories don’t capture well.

For example, the pain of knee osteoarthritis may, on closer look, come less from the joint than from the nerve circuit it has awakened. The chart then carries two entries — ① osteoarthritis (the degeneration on imaging, which may be separate from today’s pain) and ② post-arthritic neuropathic pain (the actual cause, and what this treatment aims at).

NNPS is judged by clinical signs, not duration — hyperalgesia, allodynia, and persistent pain mark grade I; added emotional and cognitive distress marks grade II. Tests such as DITI (thermography) and fMRI can support the picture, but cost and complexity keep clinical judgment first.

04 Aiming

So what does it target, and how

If the driver is the circuit, it is logical to aim at the nodes of that circuit rather than add to the surface tissue. The core of the M-puncture technique, as the textbook describes it, is:

• A fine needle disturbs the pain nerve (C-fiber) as little as possible while stimulating other sensory nerve (Aδ)
• It works by ‘zone’ rather than a single point — an area, not a dot
• What it aims at: the first lesion (PML), the spinal lesion (SML), and the descending control pathway (activating D.I, modulating D.F)
• For descending control, it also stimulates specific zones of the face (trigeminal V1), the ear region (V3, vagus), and the neck (C2, C3)
• Segmental control — using the pain site (PSC) and its distal bordering zone (DSC)

The authors distinguish this from conventional acupuncture/dry needling. Where the conventional route dampens ‘pain with pain’ indirectly, M-puncture is described as aiming at the lesion directly (citing molecular pain-processing research from 1999 onward).

05 Meeting today’s pain medicine

‘Molecular lesion’ and ‘nociplastic pain’ point to the same thing

Here is the interesting part. What the authors called a ‘molecular-level lesion’ in 2009–2013, pain medicine has — since 2017 — taken into its standard framework under the names nociplastic pain and central sensitization. Only the name differed; the thing targeted is much the same.

In other words, the diagnostic frame — seeing long-standing pain as a disease of the circuit — is no longer this treatment’s claim alone but a shared view. What remains distinctive is therefore not the diagnosis but the treatment — which is why the next section matters.